A Phase 3 interventional study of Mosapride and Placebo Oral Tablet in Prevention of Postoperative Ileus, sponsored by Benha University. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2018-08-14.
Sponsored by Benha University · Phase 3, Interventional, and Prevention
Giving women one day before and immediately after cesarean section a mouthly dissolving mosapride tablets 2every every 8 hours for maximum of 5 days ,or getting recovered gastrointestinal functions And assess preoperative gastrointestinal functions
Uncomplicated post cesarean women one day before and immediately after elective cesarean receive 2 mouthly dissolving mosapride tablets every 8 hours maximum for 5 days and clinical care giver follow the woman's gastrointestinal functions, including intraoperative and postoperative nausea vomiting, passing flatus, hearing intestinal sounds, passing stools, occurring of paralytic ileus, length of the hospital stay
167 studies on the registry are indexed under Ileus; 23 are open to participants now.
This study's enrollment of 400 is above the median of 90 across 138 interventional studies indexed under Ileus.
Browse Ileus studies →Benha University is the lead sponsor of 362 studies on the registry; 66 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Fluxopride 5mg of Macryrl egypt 2 tablets one day before and immediately after elective cesarean section every 8hour for maximum of 5 days
Drug: Mosapride
Dummy identical tablets taken in the same way
Drug: Placebo Oral Tablet
Intake mouthly dissolving mosapride tablets in immediate post cesarean section
Also known as: Fluxopride
Dummy identical tablets to mouthly dissolving mosapride tablets
Also known as: Placebo
Time of first flatus
Clinical
Time frame: 96 hours postoperative
Paralytic ileus incidence and its severity
Clinical
Time frame: 7days
Toleration of fluids and solids intake
Clinical
Time frame: 2 weeks postoperative
Incidence of intraoperative and postoperative nausea and vomiting
Clinical
Time frame: Intraoperative and 2 weeks postoperative
First defecation
Clinical
Time frame: 2 weeks postoperative
Plan to share: Yes — Once data collected and analyzed and published
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When data became available and for ever
Access criteria: Any
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mosapride